1
|
Akhtar N, Ashford MB, Beer L, Bowes A, Bristow T, Broo A, Buttar D, Coombes S, Cross R, Eriksson E, Guilbaud JB, Holman SW, Hughes LP, Jackman M, Lawrence MJ, Lee J, Li W, Linke R, Mahmoudi N, McCormick M, MacMillan B, Newling B, Ngeny M, Patterson C, Poulton A, Ray A, Sanderson N, Sonzini S, Tang Y, Treacher KE, Whittaker D, Wren S. The Global Characterisation of a Drug-Dendrimer Conjugate - PEGylated poly-lysine Dendrimer. J Pharm Sci 2023; 112:844-858. [PMID: 36372229 DOI: 10.1016/j.xphs.2022.11.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2022] [Revised: 11/07/2022] [Accepted: 11/07/2022] [Indexed: 11/13/2022]
Abstract
The recent emergence of drug-dendrimer conjugates within pharmaceutical industry research and development introduces a range of challenges for analytical and measurement science. These molecules are very high molecular weight (100-200kDa) with a significant degree of structural complexity. The characteristics and quality attributes that require understanding and definition, and impact efficacy and safety, are diverse. They relate to the intact conjugate, the various building blocks of these complex systems and the level of the free and bound active pharmaceutical ingredient (API). From an analytical and measurement science perspective, this necessitates the measurement of the molecular weight, impurity characterisation, the quantitation of the number of conjugated versus free API molecules, the determination of the impurity profiles of the building blocks, primary structure and both particle size and morphology. Here we report the first example of a global characterisation of a drug-dendrimer conjugate - PEGylated poly-lysine dendrimer currently under development (AZD0466). The impact of the wide variety of analytical and measurement techniques on the overall understanding of this complex molecular entity is discussed, with the relative capabilities of the various approaches compared. The results of this study are an essential platform for the research and development of the future generations of related dendrimer-based medicines.
Collapse
Affiliation(s)
- Nadim Akhtar
- New Modalities and Parenteral Development, Pharmaceutical Technology and Development, Operations, AstraZeneca, Macclesfield, UK
| | | | - Louisa Beer
- Chemical Development, Pharmaceutical Technology and Development, Operations, AstraZeneca, Macclesfield, UK
| | - Alex Bowes
- Pharmaceutical Sciences, R&D, AstraZeneca, Macclesfield SK10 2NA, UK
| | - Tony Bristow
- Chemical Development, Pharmaceutical Technology and Development, Operations, AstraZeneca, Macclesfield, UK.
| | - Anders Broo
- Pharmaceutical Sciences, R&D, AstraZeneca, Gothenburg, Sweden
| | - David Buttar
- Pharmaceutical Sciences, R&D, AstraZeneca, Macclesfield SK10 2NA, UK
| | - Steve Coombes
- Chemical Development, Pharmaceutical Technology and Development, Operations, AstraZeneca, Macclesfield, UK
| | - Rebecca Cross
- Chemical Development, Pharmaceutical Technology and Development, Operations, AstraZeneca, Macclesfield, UK
| | - Emma Eriksson
- Pharmaceutical Sciences, R&D, AstraZeneca, Gothenburg, Sweden
| | | | - Stephen W Holman
- Chemical Development, Pharmaceutical Technology and Development, Operations, AstraZeneca, Macclesfield, UK
| | - Leslie P Hughes
- Oral Product Development, Pharmaceutical Technology and Development, Operations, AstraZeneca, Macclesfield, UK
| | - Mark Jackman
- Pharmaceutical Sciences, R&D, AstraZeneca, Cambridge, UK
| | - M Jayne Lawrence
- Division of Pharmacy & Optometry, Stopford Building, University of Manchester, 99 Oxford Road, Manchester, M13 9PG, UK
| | - Jessica Lee
- Chemical Development, Pharmaceutical Technology and Development, Operations, AstraZeneca, Macclesfield, UK
| | - Weimin Li
- Pharmaceutical Sciences, R&D, AstraZeneca, Cambridge, UK
| | - Rebecca Linke
- Pharmaceutical Sciences, R&D, AstraZeneca, Macclesfield SK10 2NA, UK
| | - Najet Mahmoudi
- ISIS Pulsed Neutron and Muon Source, Rutherford Appleton Laboratory, Chilton, Didcot, OX11 0QX, UK
| | - Marc McCormick
- Pharmaceutical Sciences, R&D, AstraZeneca, Macclesfield SK10 2NA, UK
| | - Bryce MacMillan
- UNB MRI Centre, Department of Physics, PO Box 4400, Fredericton, NB E3B 5A3, Canada
| | - Ben Newling
- UNB MRI Centre, Department of Physics, PO Box 4400, Fredericton, NB E3B 5A3, Canada
| | - Maryann Ngeny
- Oncology Regulatory Science & Strategy, AstraZeneca, Macclesfield, UK
| | - Claire Patterson
- Pharmaceutical Sciences, R&D, AstraZeneca, Macclesfield SK10 2NA, UK
| | - Andy Poulton
- Pharmaceutical Sciences, R&D, AstraZeneca, Macclesfield SK10 2NA, UK
| | - Andrew Ray
- New Modalities and Parenteral Development, Pharmaceutical Technology and Development, Operations, AstraZeneca, Macclesfield, UK
| | - Natalie Sanderson
- Chemical Development, Pharmaceutical Technology and Development, Operations, AstraZeneca, Macclesfield, UK
| | - Silvia Sonzini
- Pharmaceutical Sciences, R&D, AstraZeneca, Cambridge, UK
| | - Yayan Tang
- Regulatory Affairs, R&D, AstraZeneca, Shanghai, China
| | - Kevin E Treacher
- New Modalities and Parenteral Development, Pharmaceutical Technology and Development, Operations, AstraZeneca, Macclesfield, UK
| | - Dave Whittaker
- Pharmaceutical Sciences, R&D, AstraZeneca, Macclesfield SK10 2NA, UK
| | - Stephen Wren
- New Modalities and Parenteral Development, Pharmaceutical Technology and Development, Operations, AstraZeneca, Macclesfield, UK
| |
Collapse
|